Navigation Links
Study shows rapamycin reverses myocardial defects in mouse model of LEOPARD syndrome
Date:2/21/2011

BOSTON Congenital heart diseases affect approximately one in 100 patients, making them the most common type of birth defect and the number-one cause of pediatric deaths.

Now a new study showing that the mTOR inhibitor drug rapamycin can reverse cardiac muscle damage in a mouse model of the congenital disease LEOPARD syndrome not only identifies the first possible medical treatment for this rare condition, but also demonstrates the importance of targeted therapies in managing congenital diseases.

The research, led by investigators at Beth Israel Deaconess Medical Center (BIDMC), is published in the March issue of the Journal of Clinical Investigation (JCI), which appears on-line today.

"The genetic mutations that alter the signaling pathways involved in cardiac development have been implicated in approximately 30 percent of the defects associated with congenital heart diseases," explains the study's senior author Maria Kontaridis, PhD, a scientist in the Division of Cardiovascular Medicine at BIDMC and Assistant Professor of Medicine at Harvard Medical School. "But the molecular underpinnings of these mutations have not been clear. This new work helps illuminate their complex biochemistry."

Kontaridis's lab investigates LEOPARD syndrome and Noonan syndrome, two of a cluster of congenital diseases known as "RASopathies," which are the result of defects caused by mutations in genes in the RAS signaling pathway.

LEOPARD syndrome affects approximately 200 individuals worldwide and is clinically distinguished by multiple lentigines (freckle-like spots on the skin), as well as craniofacial defects, deafness, and blood abnormalities which can give rise to pediatric leukemias. Hypertrophic cardiomyopathy a thickening of the heart muscle that typically leads to heart failure is also associated with LS. With the exception of lentigines, Noonan syndrome patients exhibit nearly identical features and pathologies.

Mutations in the PTPN11 (non-receptor protein tyrosine phosphatase type 11) gene are responsible for virtually all cases of LEOPARD syndrome and about half of the Noonan syndrome cases, notes Kontaridis. Consequently, LEOPARD syndrome [LS] and Noonan syndrome have traditionally been thought to be allelic variants with the same disease etiology.

But, this new study showed that this was not the case. By creating an LS mouse model that reproduced features of the human disorder, the Kontaridis group found that the mutations in PTPN11 that cause LEOPARD syndrome are distinct, and lead to a loss of phosphatase activity and hyperactivation of the AKT/mTOR pathway -- which leads to the development of hypertrophic cardiomyopathy.

"When these mice were treated with rapamycin [an mTOR inhibitor agent best known for its role as an immunosuppressant] the hypertrophic cardiomyopathy was reversed," she explains. "Our next step will be to test rapamycin in a clinical trial to evaluate the effect of this treatment in humans with LEOPARD syndrome. Patients would be enrolled on the basis of biochemical analysis [i.e. mTOR activity] rather than clinical diagnosis."

A related study in today's on-line issue of the JCI, by a team of scientists at the University Health Network, Toronto, found that in a mouse model of Noonan syndrome, excessive activity of an enzyme called ERK (a downstream target of the RAS pathway) led to the development of hypertrophic cardiomyopathy, and that treatment with an ERK inhibitor currently being tested as an anti-cancer agent, reversed the cardiomyopathy. This study was led by UHN scientists Toshiyuki Araki and Benjamin Neel, who was also a co-corresponding author on the Kontaridis paper.

"Together, these two studies demonstrate for the first time that individualized therapy should be considered for patients with RASopathy disorders," says Kontaridis. "Our findings in LEOPARD syndrome may additionally provide the first glimpse of a much broader implication -- a potential mechanism for the treatment of other, more common congenital hypertrophy disorders."


'/>"/>

Contact: Bonnie Prescott
bprescot@bidmc.harvard.edu
617-667-7306
Beth Israel Deaconess Medical Center
Source:Eurekalert

Related biology news :

1. New study illustrates shifting biomes in Alaska
2. NIFA announces grants to study the effects of climate change on agricultural and forest production
3. Study suggests statins may prevent diabetic-related blindness
4. First-of-its-kind study shows benefits of electrical stimulation therapy for people paralyzed by spinal cord injury
5. Designing new molecular tools to study the life and death of a cancer cell
6. Scripps Research study sheds light on RNA on/off switches
7. Study finds massive flux of gas, in addition to liquid oil, at BP well blowout in Gulf
8. Pulmonary fibrosis inhibited by pentraxin-2/SAP in research study
9. NSF funds study of landscape restoration effects on Pennsylvania stream
10. VTT to study one of worlds oldest beers
11. Brandeis study shows economic impact of dengue virus in Americas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2016)... -- Securus Technologies, a leading provider of civil and ... and monitoring, announced today that it has offered a ... independent technology judge determine who has the largest and ... calling platform, and the best customer service. ... what we do – which clearly is not the ...
(Date:11/16/2016)... 2016 Sensory Inc ., a ... for consumer electronics, and VeriTran , a ... industry, today announced a global partnership that will ... authenticate users of mobile banking and mobile payments ... software which requires no specialized biometric scanners, yet ...
(Date:11/14/2016)... -- xG Technology, Inc. ("xG" or the "Company") (Nasdaq: XGTI, ... use in challenging operating environments, announced its results for ... hold a conference call to discuss these results on ... below). Key Recent Accomplishments ... to acquire Vislink Communication Systems. The purchase is expected ...
Breaking Biology News(10 mins):
(Date:12/9/2016)... ... December 09, 2016 , ... There’s a winning streak at Voxx ... Orange County Register, after winning the award last year as well. Employees nominate their ... and COO Daniel Vesely pointed to the tech company’s upbeat environment as a reason. ...
(Date:12/9/2016)... ... December 09, 2016 , ... Aditya Humad, Acting CFO of AxioMed and ... and the United States, Axiomed is now gaining interest from Silicon Valley. “It was ... Mr. Humad went on to say that, “We expect interest to continue to rise ...
(Date:12/9/2016)... , Dec. 9, 2016  A platform of ... are moving one step closer to becoming viable ... OrthoMend Research, Inc., a start-up company from ... exclusive license for these novel absorbable bone fixation ... them for commercial use. The company has leased ...
(Date:12/9/2016)... Dec. 9, 2016 /PRNewswire/ - Portage Biotech Inc. ("Portage" ... is pleased to announce that Biohaven has issued today ... Haven, Connecticut (PRWEB) Dec 9, 2016 - ... announced today that the U.S. Food and Drug Administration ... covering its drug candidate BHV-0223, an orally dissolving tablet ...
Breaking Biology Technology: